Here is your quote:
Exactly, RPRX is in good shape if the FDA decides they don't need libido studies to obtain an approval for Androxal, however, at what price would RPRX do another financing if QOL's are needed?
Once again, and read carefully, because there is a myth going around, possibly propagated in part by me- apologies if so, that some quality of life marker will put a clinical or negotiatory (is that a word?) HOLD on Androxal development. I have been told unequivocally NOT by two people that I absolutely trust to know their stuff, that this is NOT the case.
In fact, I was told this analogy recently: Your wife says, "go buy me a pair of shoes" and you go out and do trial and error, you may never get satisfaction on the task. If the FDA says, "we want red pumps" then Repros can and will develop that study and will still be able to commence finding a suitor, partner or buyer very quickly, within 6-9 months.
Read what docbanker posted earlier; they may sell the clinical rights to develop proellex for the breast cancer indication for 20 Mil, for example. That negates the need for money completely.
AND, if they really do get completely snubbed by the FDA, meaning the FDA says "we do not know what we need to see, go do a trial and then come back to us with what you study and the results and we 'll see about approving your drug", then the halt Androxal development and they then have enough cash to develop the whole Proellex program through to NDA....
It's high time people get off this raising money issue...
It won't need to happen, with about 80% assurance, and if it does, there's only 12 million shares outstanding for gosh sakes. We're not talking diluting with 20 million more shares, we MIGHT be talking in the range of another 1-1.5 M shares, AFTER the next round of superior data in efficacy and safety, at 20 per share... or more!
News 
Market Data 
Discover 
AI
